<DOC>
	<DOCNO>NCT01989585</DOCNO>
	<brief_summary>This partially randomized phase I/II trial study side effect best dose dabrafenib , trametinib , navitoclax see well work treat patient v-raf murine sarcoma viral oncogene homolog B ( BRAF ) mutant melanoma solid tumor spread part body remove surgery . Dabrafenib , trametinib , navitoclax may stop growth tumor cell block enzymes need cell growth .</brief_summary>
	<brief_title>Dabrafenib , Trametinib , Navitoclax Treating Patients With BRAF Mutant Melanoma Solid Tumors That Are Metastatic Can Be Removed Surgery</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose ( MTD ) , toxicity , safety profile navitoclax give combination dabrafenib trametinib patient BRAF-mutant solid tumor . ( Phase I ) II . To estimate complete response ( CR ) rate patient BRAF-mutant melanoma treat dabrafenib , trametinib , navitoclax compare historical control dabrafenib trametinib combination ( DT ) . ( Phase II ) III . To compare maximal tumor regression patient BRAF-mutant melanoma treat dabrafenib , trametinib versus dabrafenib , trametinib , navitoclax . ( Phase II ) SECONDARY OBJECTIVES : I . To describe pharmacodynamics effect treatment dabrafenib , trametinib , navitoclax serial tumor biopsy serial blood draw small subset patient treat BRAF-mutant melanoma . ( Phase I ) II . To describe pharmacokinetics treatment dabrafenib , trametinib , navitoclax . ( Phase I ) III . To compare progression-free survival ( PFS ) , overall survival ( OS ) , overall response rate ( ORR ) patient BRAF-mutant melanoma treat dabrafenib , trametinib , versus dabrafenib , trametinib , navitoclax . ( Phase II ) IV . To compare degree apoptosis induce on-treatment biopsy patient BRAF-mutant melanoma treat dabrafenib , trametinib versus dabrafenib , trametinib , navitoclax . ( Phase II ) V. To explore pharmacodynamic effect on-treatment biopsy patient BRAF-mutant melanoma treat either dabrafenib , trametinib versus dabrafenib , trametinib , navitoclax include cell proliferation ( Ki-67 ) , proteomics ( reverse-phase protein microarrays [ RPPA ] ) , B-cell chronic lymphocytic leukemia ( CLL ) /lymphoma 2 ( BCL-2 ) family gene expression analysis . ( Phase II ) OUTLINE : This phase I , dose-escalation study dabrafenib , trametinib , navitoclax follow randomized phase II study . PHASE I : Patients receive navitoclax orally ( PO ) daily ( QD ) day -7 -1 course 1 . Patients also receive dabrafenib PO twice daily ( BID ) , trametinib PO QD , navitoclax PO QD day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . PHASE II : Patients randomize 1 2 treatment arm . ARM I : Patients receive dabrafenib PO BID trametinib PO QD day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . ARM II : Patients receive navitoclax PO QD day -7 -1 course 1 . Patients also receive dabrafenib PO BID , trametinib PO QD , navitoclax PO QD day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow 28 day .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Navitoclax</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<criteria>FOR PHASE I : patient must histologically confirm , BRAFmutant ( V600E/K ) malignancy ( molecularly confirm use validate , commercially available assay perform Clinical Laboratory Improvement Amendments [ CLIA ] approve laboratory ) metastatic unresectable standard curative palliative measure exist longer effective If test CLIAcertified lab use nonFood Drug Administration ( FDA ) approve method , information assay must provide ; ( FDA approve test BRAF V600 mutation melanoma include : THxID BRAF Detection Kit Cobas 4800 BRAF V600 mutation test ) FOR PHASE II : patient must histologically confirm , BRAFmutant ( V600E/K ) melanoma ( molecularly confirm use validate , commercially available assay perform CLIAapproved laboratory ) metastatic unresectable standard curative measure exist longer effective If test CLIAcertified lab use nonFDA approved method , information assay must provide ; ( FDA approve test BRAF V600 mutation melanoma include : THxID BRAF detection kit Cobas 4800 BRAF V600 mutation test ) Patients must measurable disease , define least one lesion accurately measure least one dimension ( long diameter record nonnodal lesion short axis nodal lesion ) &gt; = 20 mm conventional technique &gt; = 10 mm spiral compute tomography ( CT ) scan , magnetic resonance imaging ( MRI ) , caliper clinical exam Prior therapy allow : Phase I : patient enrol phase I portion study , patient may receive number prior line therapy include treatment BRAF and/or mitogenactivated protein kinase kinase ( MEK ) inhibitor ; prior navitoclax use allow , unless patient receive &lt; 7 day navitoclax leadin another study stop reason toxicity disease progression Phase II : patient enrol phase II portion study , patient may receive prior immunotherapy ( include highdose interleukin [ IL ] 2 , ipilimumab , nivolumab , antiprogrammed cell death 1 [ PD1 ] /programmed cell death 1 ligand 1 [ PDL1 ] antibody ) chemotherapy , however prior navitoclax , BRAF inhibitor and/or MEK inhibitor therapy allow Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 1 ( Karnofsky &gt; = 70 % ) Life expectancy great 3 month Leukocytes &gt; = 3,000/mcL Absolute neutrophil count &gt; = 1 x 10^9/L Hemoglobin &gt; = 9 g/dl ( patient may transfuse level ) Platelets &gt; = 100,000/mcL Total bilirubin = &lt; 1.5 x institutional upper limit normal OR &gt; 1.5 x institutional upper limit normal allow direct bilirubin within normal range Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 2.5 x institutional upper limit normal Prothrombin time ( PT ) /international normalize ratio ( INR ) partial thromboplastin time ( PTT ) &lt; 1.3 x upper limit normal ( ULN ) Serum creatinine = &lt; 1.5 mg/dL OR creatinine clearance &gt; = 50 mL/min/1.73 m^2 Left ventricular ejection fraction &gt; = institutional low limit normal ( LLN ) echocardiogram ( ECHO ) Patients must correct QT ( QTc ) interval le 480 msec Women childbearing potential men must agree use adequate contraception ( barrier method birth control , abstinence ; hormonal contraception allow ) prior study entry , duration study participation , 4 month completion study drug administration ; woman become pregnant suspect pregnant participating study , inform treat physician immediately Therapeutic level dose warfarin use close monitoring PT/INR site ; exposure may decrease due enzyme induction treatment , thus warfarin dose may need adjust base upon PT/INR ; consequently , discontinue dabrafenib , warfarin exposure may increase thus close monitoring via PT/INR warfarin dose adjustment must make clinically appropriate ; prophylactic low dose warfarin may give maintain central catheter patency Able swallow retain oral medication must clinically significant gastrointestinal abnormality may alter absorption malabsorption syndrome major resection stomach bowel Ability understand willingness sign write informed consent document Patients immunotherapy , chemotherapy radiotherapy within 14 day prior first dose navitoclax , prior systemic anticancer therapy ( chemotherapy delay toxicity , extensive radiation therapy , immunotherapy , biologic therapy , vaccine therapy ) within last 3 week prior first dose dabrafenib and/or trametinib ; chemotherapy regimens without delayed toxicity within last 2 week precede first dose study treatment ; biologics allow within 30 day prior , , navitoclax administration In phase I portion study , patient must receive prior navitoclax , unless patient receive &lt; 7 day navitoclax leadin another study stop reason toxicity disease progression ; phase II portion study , prior navitoclax , BRAF inhibitor MEK inhibitor prohibit Patients receive investigational agent receive investigational drug within 28 day ( five halflives , whichever short ; minimum 14 day last dose ) precede first dose study treatment study Patients must clinical evidence leptomeningeal brain metastasis cause spinal cord compression symptomatic untreated stable &gt; = 3 month ( must document imaging ) require corticosteroid ; subject stable dose corticosteroid &gt; 1 month corticosteroid least 2 week enrol approval Cancer Therapy Evaluation Program ( CTEP ) medical monitor ; subject must also enzymeinducing anticonvulsant &gt; 4 week History allergic reaction attribute compound similar chemical biologic composition navitoclax , dabrafenib , trametinib , excipients dimethyl sulfoxide ( DMSO ) Uncontrolled intercurrent illness include , limited , ongoing active serious infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , uncontrolled diabetes , psychiatric illness/social situation would limit compliance study requirement Pregnant woman exclude study ; breastfeed discontinue mother treat study drug Human immunodeficiency virus ( HIV ) positive patient combination antiretroviral therapy ineligible History another malignancy study indication trial within 5 year study enrollment ; apply subject underwent successful definitive resection basal squamous cell carcinoma skin , superficial bladder cancer , situ cervical cancer , situ breast cancer , situ cancer ; exception : patient history retrovirusassociated deoxyribonucleic acid ( DNA ) sequence ( RAS ) mutationpositive tumor eligible regardless interval current study ; prospective RAS testing require ; however , result previous RAS test know , must use assess eligibility History interstitial lung disease pneumonitis History current evidence/risk retinal vein occlusion ( RVO ) central serous retinopathy ( CSR ) : History RVO CSR , predispose factor RVO CSR ( e.g. , uncontrolled glaucoma ocular hypertension , uncontrolled systemic disease hypertension , diabetes mellitus , history hyperviscosity hypercoagulability syndrome ) Visible retinal pathology assess ophthalmic exam consider risk factor RVO CSR evidence new optic disc cupping , evidence new visual field defect , intraocular pressure &gt; 21 mmHg History evidence cardiovascular risk include follow : A QT interval correct heart rate use Bazett 's formula QTcB &gt; = 480 msec History evidence current clinically significant uncontrolled arrhythmia ( exception : patient control atrial fibrillation &gt; 30 day prior randomization eligible ) History acute coronary syndrome ( include myocardial infarction unstable angina ) , coronary angioplasty , stenting within 6 month prior randomization History evidence current &gt; = class II congestive heart failure define New York Heart Association ( NYHA ) functional classification system Treatmentrefractory hypertension define blood pressure systolic &gt; 140 mmHg and/or diastolic &gt; 90 mmHg control antihypertensive therapy Abnormal cardiac valve morphology ( &gt; = grade 2 ) document echocardiogram ( subject grade 1 abnormality [ i.e. , mild regurgitation/stenosis ] enter study ) ; subject moderate valvular thickening enter study Known history hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) infection ( patient chronic clear HBV HCV infection eligible ) ; necessary conduct HBV HCV test screen Subject underlying condition predispose bleed currently exhibit sign clinically significant bleeding Subject recent history nonchemotherapyinduced thrombocytopenicassociated bleeding within 1 year prior first dose study drug A history glucose6phosphate dehydrogenase ( G6PD ) deficiency Unresolved toxicity National Cancer Institute Common Terminology Criteria Adverse Events , version 4.0 ( NCI CTCAE v4.0 ) grade 2 high previous anticancer therapy , except alopecia , time randomization The following concomitant medication allow navitoclax administration : clopidogrel , ibuprofen , tirofiban , warfarin , anticoagulant , drug , herbal supplement affect platelet function exclude , exception lowdose anticoagulation medication ( heparin ) use maintain patency central intravenous catheter ; aspirin allow within 7 day prior first dose navitoclax navitoclax administration ; however , subject previously receive aspirin therapy thrombosis prevention may resume low dose ( i.e. , maximum 100 mg QD ) aspirin platelet count stable ( &gt; = 50,000/mm^3 ) 6 week navitoclax administration ; decision regard treatment aspirin therapy determine investigator conjunction medical monitor Current use prohibit medication ; follow medication nondrug therapy prohibit : Other anticancer therapy study treatment ; ( note : megestrol [ Megace ] use appetite stimulant allow ) Concurrent treatment bisphosphonates permit ; however , treatment must initiate prior first dose study therapy ; prophylactic use bisphosphonates patient without bone disease permit , except treatment osteoporosis Concurrent use herbal supplement prohibit study ( include , limited , St. John 's wort , kava , ephedra [ huang ] , ginkgo biloba , dehydroepiandrosterone [ DHEA ] , yohimbe , saw palmetto , ginseng ) Anticoagulants antiplatelet agent except lowdose , 81 mg aspirin Caution exercise dose navitoclax concurrently cytochrome P450 , family 2 , subfamily C , peptide 8 ( CYP2C8 ) cytochrome P450 , family 2 , subfamily C , peptide 9 ( CYP2C9 ) substrates ; common CYP2C8 substrate include paclitaxel , statin , glitazones , whereas CYP2C9 substrates include phenytoin ; possible , investigator switch alternative medication monitor patient closely ; cytochrome P450 , family 3 , subfamily A ( CYP3A ) inhibitor ketoconazole clarithromycin allow 7 day prior first dose navitoclax navitoclax administration Patients receive medication substance strong inhibitor inducer CYP3A CYP2C8 ineligible ; current use , intend ongoing treatment : herbal remedy ( e.g. , St. John 's wort ) , strong inhibitor inducer permeabilityglycoprotein ( Pgp ) breast cancer resistance protein 1 ( Bcrp1 ) also exclude ; example agent : Strong inducer CYP3A CYP2C8 : Antibiotics : rifamycin class agent ( e.g. , rifampin , rifabutin , rifapentine ) Anticonvulsants : carbamazepine , oxcarbazepine , phenobarbital , phenytoin , smephenytoin Miscellaneous : bosentan , St. John 's wort Strong inhibitor CYP3A CYP2C8 Antibiotics : clarithromycin , telithromycin , troleandomycin Antidepressants : nefazodone Antifungals : itraconazole , ketoconazole , posaconazole , voriconazole Hyperlipidemia : gemfibrozil Antiretroviral : ritonavir , saquinavir , atazanavir Miscellaneous : conivaptan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>